153 related articles for article (PubMed ID: 27747105)
1. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Cao LF; Peng XY; Huang Y; Wang B; Zhou FM; Cheng RX; Chen LH; Luo WF; Liu T
Neural Plast; 2016; 2016():6383240. PubMed ID: 27747105
[TBL] [Abstract][Full Text] [Related]
2. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
3. Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson's disease.
Gao Q; Zhang Y; Wang X; Wang R; Zhang L
CNS Neurosci Ther; 2024 Mar; 30(3):e14446. PubMed ID: 37721421
[TBL] [Abstract][Full Text] [Related]
4. Additional noradrenergic depletion aggravates forelimb akinesia and abnormal subthalamic nucleus activity in a rat model of Parkinson's disease.
Wang Y; Chen X; Wang T; Sun YN; Han LN; Li LB; Zhang L; Wu ZH; Huang C; Liu J
Life Sci; 2014 Dec; 119(1-2):18-27. PubMed ID: 25445222
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
[TBL] [Abstract][Full Text] [Related]
6. Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Scalori V; Corsini GU
Ann N Y Acad Sci; 1998 May; 844():166-77. PubMed ID: 9668674
[TBL] [Abstract][Full Text] [Related]
7. Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA.
Kehne JH; Davis M
Brain Res; 1985 Mar; 330(1):31-41. PubMed ID: 3921192
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
9. Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Kääriäinen TM; Käenmäki M; Forsberg MM; Oinas N; Tammimäki A; Männistö PT
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):162-70. PubMed ID: 21848668
[TBL] [Abstract][Full Text] [Related]
10. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
11. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
Rampersaud N; Harkavyi A; Giordano G; Lever R; Whitton J; Whitton P
Br J Pharmacol; 2012 Dec; 167(7):1467-79. PubMed ID: 22774922
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
14. Effect of spinal monoaminergic neuronal system dysfunction on pain threshold in rats, and the analgesic effect of serotonin and norepinephrine reuptake inhibitors.
Tamano R; Ishida M; Asaki T; Hasegawa M; Shinohara S
Neurosci Lett; 2016 Feb; 615():78-82. PubMed ID: 26806036
[TBL] [Abstract][Full Text] [Related]
15. Sex-related differences in descending norepinephrine and serotonin controls of spinal withdrawal reflex during intramuscular saline induced muscle nociception in rats.
Lei J; Jin L; Zhao Y; Sui MY; Huang L; Tan YX; Chen YK; You HJ
Exp Neurol; 2011 Apr; 228(2):206-14. PubMed ID: 21238453
[TBL] [Abstract][Full Text] [Related]
16. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
17. The antihyperalgesic effects of intrathecal bupropion, a dopamine and noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
Hoshino H; Obata H; Nakajima K; Mieda R; Saito S
Anesth Analg; 2015 Feb; 120(2):460-6. PubMed ID: 25427287
[TBL] [Abstract][Full Text] [Related]
18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
19. The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
Song L; Yang X; Ma Y; Wu N; Liu Z
Drug Des Devel Ther; 2014; 8():2173-9. PubMed ID: 25395834
[TBL] [Abstract][Full Text] [Related]
20. Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model.
Takeuchi Y; Takasu K; Ono H; Tanabe M
Neuropharmacology; 2007 Dec; 53(7):842-53. PubMed ID: 17889907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
